ResearcherHokkaido UniversityNo recent work listed
Fumihiko Matsuzawa
Matched on OpenAlex author ID A5083151002. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2018: 1 paper · 2019: none · 2020: none · 2021: 2 papers
Papers 3
- Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreat… Co-author DOI 10.1007/s10637-021-01118-1↗
- Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive panc… Co-author DOI 10.1186/s12885-020-07722-3↗
- The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in … Co-author DOI 10.18632/oncotarget.26117↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Tatsuzo Mizukami · 3 shared papers, 2018–2021 · strength 0.36
- Paper Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver meta… DOI 10.1007/s10637-021-01118-1↗
- Paper Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer c… DOI 10.1186/s12885-020-07722-3↗
- Paper The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-hig… DOI 10.18632/oncotarget.26117↗
- Hirofumi Kamachi · 3 shared papers, 2018–2021 · strength 0.36
- Paper Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver meta… DOI 10.1007/s10637-021-01118-1↗
- Paper Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer c… DOI 10.1186/s12885-020-07722-3↗
- Paper The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-hig… DOI 10.18632/oncotarget.26117↗
- Akinobu Taketomi · 3 shared papers, 2018–2021 · strength 0.36
- Paper Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver meta… DOI 10.1007/s10637-021-01118-1↗
- Paper Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer c… DOI 10.1186/s12885-020-07722-3↗
- Paper The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-hig… DOI 10.18632/oncotarget.26117↗
- Yuki Fujii · 2 shared papers, 2021 · strength 0.28
- Paper Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver meta… DOI 10.1007/s10637-021-01118-1↗
- Paper Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer c… DOI 10.1186/s12885-020-07722-3↗
- Takahiro Einama · 2 shared papers, 2018–2021 · strength 0.21
- Paper Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer c… DOI 10.1186/s12885-020-07722-3↗
- Paper The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-hig… DOI 10.18632/oncotarget.26117↗
- Yuki Fujii · 1 shared paper, 2018 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.